223 related articles for article (PubMed ID: 15382153)
1. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis.
Yokohama S; Yoneda M; Haneda M; Okamoto S; Okada M; Aso K; Hasegawa T; Tokusashi Y; Miyokawa N; Nakamura K
Hepatology; 2004 Nov; 40(5):1222-5. PubMed ID: 15382153
[TBL] [Abstract][Full Text] [Related]
2. [Clinical utility of angiotensin II receptor antagonist].
Yokohama S; Nakamura K; Haneda M
Nihon Rinsho; 2006 Jun; 64(6):1152-6. PubMed ID: 16768124
[TBL] [Abstract][Full Text] [Related]
3. Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis.
Ibañez P; Solis N; Pizarro M; Aguayo G; Duarte I; Miquel JF; Accatino L; Arrese M
J Gastroenterol Hepatol; 2007 Jun; 22(6):846-51. PubMed ID: 17565640
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study.
Georgescu EF; Georgescu M
J Gastrointestin Liver Dis; 2007 Mar; 16(1):39-46. PubMed ID: 17410287
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of Ob-Rb and its relationship with the overexpression of TGF-beta1 and the stage of fibrosis in patients with nonalcoholic steatohepatitis.
Cayón A; Crespo J; Mayorga M; Guerra A; Pons-Romero F
Liver Int; 2006 Nov; 26(9):1065-71. PubMed ID: 17032406
[TBL] [Abstract][Full Text] [Related]
6. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis.
Ito S; Yukawa T; Uetake S; Yamauchi M
Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S83-7. PubMed ID: 17331172
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis.
Satapathy SK; Sakhuja P; Malhotra V; Sharma BC; Sarin SK
J Gastroenterol Hepatol; 2007 May; 22(5):634-8. PubMed ID: 17444848
[TBL] [Abstract][Full Text] [Related]
8. Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats.
Kaji K; Yoshiji H; Kitade M; Ikenaka Y; Noguchi R; Shirai Y; Aihara Y; Namisaki T; Yoshii J; Yanase K; Tsujimoto T; Kawaratani H; Fukui H
Am J Physiol Gastrointest Liver Physiol; 2011 Jun; 300(6):G1094-104. PubMed ID: 21372165
[TBL] [Abstract][Full Text] [Related]
9. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
Renke M; Tylicki L; Rutkowski P; Wojnarowski K; Lysiak-Szydlowska W; Rutkowski B
Scand J Urol Nephrol; 2005; 39(6):511-7. PubMed ID: 16303729
[TBL] [Abstract][Full Text] [Related]
10. Obesity-related non-alcoholic steatohepatitis and TGF-beta1 serum levels in relation to morbid obesity.
Sepúlveda-Flores RN; Vera-Cabrera L; Flores-Gutiérrez JP; Maldonado-Garza H; Salinas-Garza R; Zorrilla-Blanco P; Bosques-Padilla FJ
Ann Hepatol; 2002; 1(1):36-9. PubMed ID: 15114294
[TBL] [Abstract][Full Text] [Related]
11. Molecular and clinical response to angiotensin II receptor antagonist in kidney transplant patients with chronic allograft nephropathy.
Mas VR; Alvarellos T; Maluf DG; Ferreira-Gonzalez A; Oliveros L; Maldonado RA; de Boccardo G
Transpl Int; 2004 Oct; 17(9):540-4. PubMed ID: 15349718
[TBL] [Abstract][Full Text] [Related]
12. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy.
Javor ED; Ghany MG; Cochran EK; Oral EA; DePaoli AM; Premkumar A; Kleiner DE; Gorden P
Hepatology; 2005 Apr; 41(4):753-60. PubMed ID: 15791619
[TBL] [Abstract][Full Text] [Related]
13. The risk factors of fibrosis in nonalcoholic steatohepatitis.
Fierbinţeanu-Braticevici C; Bengus A; Neamţu M; Usvat R
Rom J Intern Med; 2002; 40(1-4):81-8. PubMed ID: 15526543
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis.
Yokohama S; Tokusashi Y; Nakamura K; Tamaki Y; Okamoto S; Okada M; Aso K; Hasegawa T; Aoshima M; Miyokawa N; Haneda M; Yoneda M
World J Gastroenterol; 2006 Jan; 12(2):322-6. PubMed ID: 16482638
[TBL] [Abstract][Full Text] [Related]
15. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study.
Abdelmalek MF; Angulo P; Jorgensen RA; Sylvestre PB; Lindor KD
Am J Gastroenterol; 2001 Sep; 96(9):2711-7. PubMed ID: 11569700
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.
Hyogo H; Tazuma S; Arihiro K; Iwamoto K; Nabeshima Y; Inoue M; Ishitobi T; Nonaka M; Chayama K
Metabolism; 2008 Dec; 57(12):1711-8. PubMed ID: 19013295
[TBL] [Abstract][Full Text] [Related]
17. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.
Ong JP; Elariny H; Collantes R; Younoszai A; Chandhoke V; Reines HD; Goodman Z; Younossi ZM
Obes Surg; 2005 Mar; 15(3):310-5. PubMed ID: 15826462
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of serum hepatic fibrosis markers in the diagnosis of nonalcoholic steatohepatitis (NASH).
Sasaki N; Ueno T; Morita Y; Nagata E; Sata M
Hepatogastroenterology; 2006; 53(71):678-81. PubMed ID: 17086867
[TBL] [Abstract][Full Text] [Related]
19. Relationship between serum ferritin, hepatic iron staining, diabetes mellitus and fibrosis progression in patients with chronic hepatitis C.
D'Souza RF; Feakins R; Mears L; Sabin CA; Foster GR
Aliment Pharmacol Ther; 2005 Mar; 21(5):519-24. PubMed ID: 15740534
[TBL] [Abstract][Full Text] [Related]
20. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis.
Bahcecioglu IH; Yalniz M; Ataseven H; Ilhan N; Ozercan IH; Seckin D; Sahin K
Hepatogastroenterology; 2005; 52(65):1549-53. PubMed ID: 16201116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
